



CANNABIS
LEGAL GROUP



MEDICAL MARIJUANA WHAT DOES THE RESEARCH SAY?



MEDICAL MARIJUANA

WHAT DOES THE RESEARCH SAY?

In 1999, the Congressionally chartered Institute of Medicine (here called “IOM”), which is a part of the National Academy of Sciences, did the most extensive review of the medical literature on marijuana to date and concluded that:

“[t]he accumulated data indicate a potential therapeutic value for cannabinoid drugs, particularly for symptoms such as pain relief, control of nausea and vomiting, and appetite stimulation.” There is “substantial consensus among experts in the relevant disciplines on the scientific evidence about potential medical uses of marijuana.” ¹

Since that time, numerous other studies about therapeutic and palliative benefits of medical marijuana, as well as some of the risks associated with its use, have emerged.

Below are some of the key findings and most recent studies concerning medical marijuana and its derivatives. This summary is not, however, a summary of all the scientific literature.

In general, research supports the IOM report finding that medical marijuana is safe and effective in controlling chronic pain, alleviating nausea and vomiting associated with chemotherapy, treating wasting syndrome associated with AIDS, and controlling muscle spasms due to multiple sclerosis and epilepsy. ^{2, 3}

Cancer and Chemotherapy

Studies of medical marijuana and cancer have focused both on the ability of medical marijuana to alleviate the symptoms of chemotherapy and the potential for cannabinoids to reduce the growth of certain types of cancer.

A 2003 review of the literature concluded cannabinoids (the active ingredients in cannabis) exert palliative effects in cancer patients by preventing nausea, vomiting and pain and by stimulating appetite. In addition to helping with the side-effects of treatment, several studies have suggested that cannabinoids may stop many kinds of cancers from growing and



spreading, including pancreatic, lung, leukemic, melanoma, oral, lymphoma and other kinds of cancer. *4, 5, 6, 7, 8, 9, 10 and 11*

A significant proportion of oncologists support medical marijuana as an option for their patients. Survey data from a 1990 random sample study, long before any state had approved medical use, shows that 44% of oncologists had recommended cannabis to at least some of their patients, and more said they would do so if the laws were changed. Of the respondents expressing an opinion, a majority (54%) thought cannabis should be available by prescription.¹²

Multiple Sclerosis

Several studies have demonstrated the efficacy of medical marijuana and its derivatives in reducing spasticity and pain in multiple sclerosis (MS) patients. For example, in a randomized controlled trial, it was found that cannabis-based medicine is effective in reducing pain and sleep disturbance in MS patients with central neuropathic pain.

Similarly, double-blind randomized controlled studies demonstrated significant improvements in spasticity as well as in measures of disability, cognition, mood, sleep and fatigue among MS patients taking cannabis-based medications. A 2004, study also found that cannabis helped alleviate problems with bladder dysfunction in MS patients and improved patient self-assessment of pain, spasticity and sleep quality. *13, 14, 15, 16*

HIV/Aids

Medical marijuana has been effective in treating both the symptoms of HIV/AIDS and the side effects of some of the antiretroviral medications used to treat it. For example, medical marijuana has been found especially effective at treating neuropathic pain, a common symptom among those living with HIV/AIDS. In a double-blind randomized clinical trial, the proportion of subjects achieving at least some pain relief was found to be significantly greater with cannabis (46%) as compared to a placebo (18%). The authors noted that smoked cannabis was generally well-tolerated. *17, 18*

Medical marijuana also seems to help with nausea and weight loss among people living with HIV/AIDS. In a 2005 survey of HIV-positive medical marijuana users, 93 percent said



the drug helped decrease nausea and other symptoms, 56% said their nausea was “much better,” while 37% said it was a “little better.” In a 2007 double-blind clinical trial published in JAIDS, it was found that HIV-positive marijuana smokers increased daily caloric intake and body weight with few adverse effects.^{19, 20}

Finally, a recent study by researchers at Mt. Sinai Hospital suggests that marijuana or its derivatives have potential to inhibit a type of human immunodeficiency virus (HIV) found in late-stage AIDS. They found that marijuana receptors located on immune cells -- called cannabinoid receptors CB1 and CB2 -- can influence the spread of the virus.²¹

Pain

Numerous studies have affirmed the analgesic effects of medical marijuana. In his recent review of the literature, Kraft concluded that, while the evidence did not support the use of medical marijuana for acute pain, “in chronic pain and (painful) spasticity, an increasing number of randomized, double-blind, placebo controlled studies have shown some efficacy of cannabinoids.” As suggested above, marijuana has been especially effective for neuropathic pain, and an increasing body of research indicates that is helpful for chronic pain as well.^{22, 23, 24, 25, 26}

Irritable Bowel Syndrome and Crohn's Disease

Recent research suggests that cannabis may also be useful for patients with irritable bowel syndrome (IBS) or Crohn's disease. A 2012 study found three months' treatment with inhaled cannabis improved quality of life measurements, disease activity index, and weight gain patients with longstanding IBS. A recent observational study suggests that cannabis can help alleviate the severity of disease symptoms and reduce the need for other medications and/or surgery.^{27, 28}

Safety of Medical Marijuana

Medical marijuana is generally safe and well-tolerated, though, like any medication, it poses some risks. Smoking of any sort can cause inflammation in the lungs and should be avoided in patients with compromised lungs. However, a recent article in the Journal of American Medicine, based on a 20-year longitudinal pulmonary health study, suggests that some of these risks may



have been overstated. The authors concluded, “[m]arijuana may have beneficial effects on pain control, appetite, mood, and management of other chronic symptoms. Our findings suggest that occasional use of marijuana for these or other purposes may not be associated with adverse consequences on pulmonary function.” Patients can also avoid many of the risks associated with smoking by using vaporized or edible forms of cannabis. 29, 30

Safety of Medical Marijuana Compared to Other Medications

Compared to other medications, marijuana has low toxicity and is extremely safe.

There is no known case of an overdose death from marijuana.

In contrast, a review of deaths from the FDA Adverse Reporting System between 1997 (the year the first medical marijuana program began) and 2005 showed 196 deaths from antiemetics (medications to prevent nausea and vomiting) and 118 deaths from antispasmodics (medications that suppress muscle spasms). Opioid pain medications, which are widely prescribed, are now responsible for more accidental deaths than traffic accidents; almost 15,000 people died from prescription pain medications in 2008 alone.

Some researchers have begun looking to medical marijuana as safer and less addictive analgesic alternative to prescription opioids. For example, in a recent article in the *American Journal of Hospice and Palliative Care*, the author calls for reclassifying cannabis both to improve palliative care and to reduce opioid-related morbidity.

In a survey of medical marijuana patients, it was found that 66% had used medical marijuana as a substitute for other prescription drugs, citing fewer adverse side effects, better symptom management, and less severe withdrawal symptoms. 31, 32

There is, however, some evidence to suggest that marijuana may exacerbate psychotic symptoms among those with pre-existing signs of psychosis. The causal direction of the link between marijuana use and schizophrenia has not been established, and there has been no rise in the prevalence of schizophrenia over the last 50 years despite increasing rates of marijuana use in the general population. 33, 34, 35, 36



Addictive Potential of Medical Marijuana and Its Role in Other Drug Use

While marijuana use can become a problem for some, the 1999 National Academy of Sciences (NAS) study concluded that: “few marijuana users become dependent on it...and marijuana dependence appears to be less severe than dependence on other drugs.”

According to the National Institute for Drug Abuse only about 9% of those who try marijuana ever become addicted, compared to 32% of tobacco and 15% of alcohol users. Moreover, there is no convincing evidence that marijuana is a “gateway drug.” What the gateway theory presents as a causal explanation is rather a statistic association between common and uncommon drugs. Marijuana is the most popular illegal drug in the United States. Therefore, people who have used less popular drugs such as heroin, cocaine, and LSD are more likely to have used marijuana. 37, 38, 39

Alternatives to Medical Marijuana

Marinol, an oral medication that is currently available by prescription, is not a viable solution for many patients. Marinol contains 100% delta-9 THC (versus the 20% THC found in natural cannabis). Many patients find Marinol is too sedating and creates too many unwanted psychoactive effects. Research has also shown that Marinol is often poorly absorbed, and patients complain that dosage is hard to monitor and control. In addition, for patients suffering from severe nausea and vomiting or who cannot swallow, oral medications are often not viable. Smoked or inhaled cannabis provides an effective and efficient system for delivering THC (one of the active ingredients in marijuana). This rapid onset of effects, not only provides more immediate relief, but also allows patients to carefully titrate their dose to relieve their symptoms. 40, 41, 42

Medical Marijuana’s Impact on Overall Drug Use

Research suggests that overall marijuana use will not increase under the tightly regulated system proposed under the Medical Marijuana Facilities Licensing Act and the related administrative rules.

The 1999 NAS report found that: “[t]here is broad social concern that sanctioning the medical use of marijuana might increase its use among the general population. At this point there are



no convincing data to support this concern. The existing data are consistent with the idea that this would not be a problem if the medical use of marijuana were as closely regulated as other medications with abuse potential... No evidence suggests that the use of opiates or cocaine for medical purposes has increased the perception that their illicit use is safe or acceptable."

Since the publication of the 1999 NAS report, several other analyses, including a 2012 study published in the *Annals of Epidemiology* examined whether or not passing medical marijuana laws impact adolescent marijuana use. The authors concluded that medical marijuana laws had no discernible effects on marijuana use: "[i]f anything our estimates suggest that reported adolescent use may actually decrease after passing medical marijuana laws (p.211)."43, 44

Footnotes

1. Joy, J. , Watson S. and A . Benson. (Eds.). (1999). *Marijuana and Medicine: Assessing the Science Base*. Washington, D.C.: National Academy of Sciences.
2. Clark PA, Capuzzi K, Fick C. (2011). Medical marijuana: medical necessity versus political agenda. *Med Sci Monit.*, 17(12):249-61.
3. Amar, MB. (2006). Cannabinoids in Medicine: a review of their therapeutic potential. *Journal of Ethnopharmacology*, 105, 1-25.
4. Guzmán M. (2003). Cannabinoids: Potential Anticancer Agents. *Nat Rev Cancer*, 3(10):745-55 .
5. Carracedo et al. (2006). Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. *Cancer Research*, 66: 6748-6755.
6. Preet et al. (2008). Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. *Oncogene*, 10: 339- 346.
7. Powles et al. (2005). Cannabis-induced cytotoxicity in leukemic cell lines. *Blood*, 105: 1214-1221.
8. Casanova et al. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. *Journal of Clinical Investigation*, 111: 43-50.
9. Whyte et al. (2010). Cannabinoids inhibit cellular respiration of human oral cancer cells. *Pharmacology*, 85: 328-335.



- 10.** Gustafsson et al. (2006). Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212 is associated with ceramide accumulation and p38 activation in Mantle Cell Lymphoma. *Molecular Pharmacology*, 70: 1612-1620.
- 11.** Pastos et al. (2005). The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase-2. *Gut*, 54: 1741-1750.
- 12.** Doblin R, Kleiman MAR (1991). Marijuana as Antiemetic Medicine: A Survey of Oncologists' Experiences and Attitudes. *J Clin Oncol*, 9: 1275-1290.
- 13.** Rog DJ, Nurmikko TJ, Friede T, Young CA. (2005). Randomized, Controlled Trial of Cannabis-Based Medicines in Central Pain in Multiple Sclerosis. *Neurology*, 65(6):812-9.
- 14.** Novotna, A., Mares, J., Ratcliffe, S., et al. (2011). A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. *European Journal of Neurology*, 18: 1122–1131.
- 15.** Wade DT, Makela P, Robson P, House H, Bateman C. (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. *Mult Scler.*, 10(4):434-41.
- 16.** Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. (2004). An Open-Label Pilot Study of Cannabis-based Extracts for Bladder Dysfunction in Advanced Multiple Sclerosis, *Mult Scler.*, 10(4):425-33.
- 17.** Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. (2009). Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial. *Neuropsychopharmacology*, 34(3):672-80.
- 18.** Abrams, D., Jay, C., Shade, S. et al. (2007). Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology*, 68: 515-521.
- 19.** Woolridge, E., Barton, S. Samuel, J. et al. (2005). Cannabis Use in HIV for Pain and Other Medical Symptoms, *Journal of Pain and Symptoms Management*, 29(4): 358-67.
- 20.** Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. (2007). Dronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric Intake, Mood, and Sleep. *J Acquir Immune Defic Syndr*. 45(5): 545-54.



- 21.** Costantino CM, Gupta A, Yewdall AW, Dale BM, Devi LA, et al. (2012). Cannabinoid Receptor 2- Mediated Attenuation of CXCR4-Tropic HIV Infection in Primary CD4+ T Cells. *PLoS ONE* 7(3): e33961. doi:10.1371/journal.pone.0033961
- 22.** Kraft B. (2012). Is There Any Clinically Relevant Cannabinoid-Induced Analgesia? *Pharmacology*, 89(5-6):237-246.
- 23.** Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. (2010). Smoked Cannabis for Chronic Neuropathic Pain: A Randomized Controlled Trial. *Canadian Medical Association Journal*, 182(14): E694-701.
- 24.** Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. (2010). Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable Cancer-Related Pain. *J Pain Symptom Manage*. 39(2):167-79.
- 25.** Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. (2003). Cannabis Use for Chronic Non-Cancer Pain: Results of a Prospective Survey. *Pain*, 102(1-2):211-6.
- 26.** Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C. (2004). Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies. *Anaesthesia*, 59(5):440-52.
- 27.** Lahat A, Lang A, Ben-Horin S. (2012). Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. *Digestion*, 85(1):1-8.
- 28.** Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. (2011). Treatment of Crohn's disease with cannabis: an observational study. *Isr Med Assoc J.*, 13(8):455-8.
- 29.** Pletcher, P., Vittinghoff, E. Kalhan, R. et al., (2012) Association Between Marijuana Exposure and Pulmonary Function Over 20 Years," *JAMA*, 307(2):173-18.
- 30.** Russo, E., Mathre, ML., Byrne, A., Velin, R., Bach, P., Sanchez-Ramos, J., and Kirlin, KA. (2002). Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis. *Journal of Cannabis Therapeutics (JCT)*: 2(1): 3-57.
- 31.** Carter GT, Flanagan AM, Earleywine M, Abrams DI, Aggarwal SK, Grinspoon L. (2011). Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. *Am J Hosp Palliat Care*, 28(5):297-303.



32. Reiman. A. (2009). Cannabis as a substitute for alcohol and other drugs. *Harm Reduction Journal*, 6 (3) .
33. Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C . (2011). Continued Cannabis Use and Risk of Incidence and Persistence of Psychotic Symptoms: 10 Year Follow-up Cohort Study. *BMJ*, 342: d738.
34. Large M, Sharma S, Compton MT, Slade T, Nielssen O. (2011). Cannabis Use and Earlier Onset of Psychosis: A Systematic Meta-analysis. *Arch Gen Psychiatry*, 68(6):555-61
35. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. (2002). Cannabis use and psychosis: a longitudinal population-based study. *Am J Epidemiol.*, 15;156(4):319-27.
36. Aggarwal, S. (2012). Cannabinergic pain medicine: A concise clinical primer and survey of randomized clinical trials. *Clinical Journal of Pain*. E-pub ahead of print.
37. Joy, J., Watson S. and A . Benson. (Eds.). (1999). *Marijuana and Medicine: Assessing the Science Base*. Washington, D.C.: National Academy of Sciences.
38. National Institute of Drug Abuse. (2010). Drug Facts: Marijuana. Available at <http://www.drugabuse.gov/publications/drugfacts/marijuana> .
39. Anthony, J. C., Warner, L. A., & Kessler, R. C. (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. *Experimental and Clinical Psychopharmacology*, 2, 244– 268.
40. Carter GT, Flanagan AM, Earleywine M, Abrams DI, Aggarwal SK, Grinspoon L. (2011). Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. *Am J Hosp Palliat Care*, 28(5):297-303.
41. Grant, I. et al. (2012). Medical marijuana: clearing away the smoke. *Open Neurology Journal*, 6, 18- 25.
42. Grant, I. et al. (2012). Medical marijuana: clearing away the smoke. *Open Neurology Journal*, 6, 18- 25.
43. Joy, J. , Watson S. and A . Benson. (Eds.). (1999). *Marijuana and Medicine: Assessing the Science Base*. Washington, D.C.: National Academy of Sciences.
44. Harper, S., E. Strumpf, and J. Kaufman. (2012). Do medical marijuana laws increase marijuana use? Replication study and extension. *Annals of Epidemiology*, 22(3): 207-212.